Contact
Please use this form to send email to PR contact of this press release:
Navrogen Granted Patents on Humoral Immuno-Oncology (HIO) Technology and HIO-Refractory NAV-001 Antibody-Drug Conjugate
TO:
Nicholas Nicolaides
Navrogen Inc
+1 610-399-2717